ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 

Plasma MiRNAs and the Risk of Venous Thromboembolism in Patients with Glioblastoma: A Nested Case-control Study

1Medical University of Vienna, Wien, Wien, Austria, 2TAmiRNA GmbH, Vienna, Austria., Vienna, Wien, Austria, 3Medical University of Vienna, Department of Medicine I, Division of Oncology, Vienna, Wien, Austria, 4Medical University of Vienna, Department of Neurosurgery, Vienna, Wien, Austria, 5Department of Medicine I, Clinical Division of Haematology and Haemostaseology, Medical University of Vienna, Vienna, Wien, Austria

Abstract Number: PB0935

Meeting: ISTH 2022 Congress

Theme: Venous Thromboembolism » Cancer Associated Thrombosis

Background: Patients with high-grade gliomas are at high risk of venous thromboembolism (VTE). MicroRNAs (miRNAs) are small non-coding RNAs with multiple roles in tumor biology as well as in hemostasis.

Aims: We aimed to explore the association between miRNAs and risk of VTE in high-grade glioma.

Methods: We conducted a nested-case control study within 152 glioblastoma patients that had been included in the Vienna Cancer and Thrombosis Study (CATS), a prospective cohort study with the aim to identify risk factors for VTE in patients with newly diagnosed or recurrent cancer. At study inclusion a single blood draw is taken and patients are thereafter followed for a maximum of two years. The primary endpoint was symptomatic VTE. In total, 24 patients (16%) developed VTE. Out of the 128 patients who did not develop VTE during follow-up we randomly selected 24 age- and sex-matched controls. Four patients had to be excluded due to missing plasma samples, leading to a final group size of 21 patients with VTE (=cases) and 23 without VTE (=controls). RNA-Seq was performed in plasma by using the miND® NGS workflow and analysis pipeline (TAmiRNA, Vienna, Austria).

Results: In an exploratory analysis adjusted for platelet count, we found several miRNAs differentially expressed in controls vs. cases. miRNAs that showed the highest magnitude of downregulation in controls vs. cases were miR-224-5p, miR-4433b-3p, and miR-139-3p, while miR-454-3p, miR-183-5p, miR-122-5p, miR-122-3p, miR483-3p and miR-885-3p showed the highest magnitude of upregulation (Figure 1). However, after adjustment for multiple testing none of the results achieved statistical significance.

Conclusion(s): Several miRNAs showed a trend towards differential expression in glioblastoma patients who later developed VTE compared to patients without VTE. Larger studies are needed to clarify whether miRNAs might identify patients at high risk of VTE.

Table 1.

Table 1. Characteristics of study patients. IQR, interquartile range

Figure 1.

Figure 1. This graph visualizes the relation of the logFC -how much did a miRNA change in the controls vs. cases- and the statistical significance of this change. miRNAs higher up have a smaller p-value -unadjusted-, while miRNAs more to the left or right of the center, show a greater differential expression.

To cite this abstract in AMA style:

Riedl J, Hackl M, Diendorfer A, Preusser M, Widhalm G, Roessler K, Pabinger I, Ay C, Erhart F. Plasma MiRNAs and the Risk of Venous Thromboembolism in Patients with Glioblastoma: A Nested Case-control Study [abstract]. https://abstracts.isth.org/abstract/plasma-mirnas-and-the-risk-of-venous-thromboembolism-in-patients-with-glioblastoma-a-nested-case-control-study/. Accessed October 2, 2023.

« Back to ISTH 2022 Congress

ISTH Congress Abstracts - https://abstracts.isth.org/abstract/plasma-mirnas-and-the-risk-of-venous-thromboembolism-in-patients-with-glioblastoma-a-nested-case-control-study/